ICI was shown to significantly increase survival in stage IV NSCLC, with a 32% 5-year OS with pembrolizumab in selected patients with high programmed death-ligand 1 (PD-L1) expression, and a 62% 5-year OS with alectinib, in patients with an anaplastic lymphoma kinase (ALK) rearrangement [4,5]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.